Valuation: Atossa Therapeutics, Inc.

Market Cap 25.35M 21.71M 20.32M 18.6M 34.9M 2.43B 35.36M 240M 93.6M 1.22B 95.18M 93.11M 4.03B P/E 2026 *
-0.66x
P/E 2027 * -0.81x
Enterprise Value 25.35M 21.71M 20.32M 18.6M 34.9M 2.43B 35.36M 240M 93.6M 1.22B 95.18M 93.11M 4.03B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.3%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day-1.93%
1 week-2.31%
Current month+22.71%
1 month+5.39%
3 months-48.79%
6 months-35.86%
Current year-71.30%
1 week 2.44
Extreme 2.44
2.78
1 month 2.05
Extreme 2.05
2.97
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
19.35
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
64.65
10 years 1.7
Extreme 1.7
702
Manager TitleAgeSince
Chief Executive Officer 75 01/04/2009
Director of Finance/CFO 50 14/10/2025
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Chairman 75 01/04/2009
Director/Board Member 64 01/04/2009
Director/Board Member 79 01/07/2011
Date Insider Type Main position Quantity % Market Cap.
20/1/26 Free

Chief Executive Officer

1,281,674 0.9922%
20/1/26
Ensisheim Partners LLC
OtherCompany 0 0%
14/10/25 Free

Chief Financial Officer

578,000 0.4595%
Change 5-day change 1-year change 3-year change Capi.($)
-1.93%-2.31%-78.22%-81.19% 25.35M
-0.27%+5.26%+4.52%+23.38% 51.61B
-1.07%+2.82%+465.96%+570.70% 44.89B
+1.47%+9.79%+35.92%+20.21% 42.77B
+1.44%+7.77%+19.38%+84.65% 42.58B
-0.93%-4.33%+16.18%+55.82% 31.82B
+1.32%+7.30%+33.89%+148.53% 17.33B
-0.60%+1.93% - - 16.63B
-0.03%+4.17%+9.26%+30.26% 14.76B
+1.28%+5.41%+82.40%+46.13% 14.09B
Average +0.09%+3.95%+65.48%+99.83% 27.65B
Weighted average by Cap. +0.24%+4.72%+99.71%+141.38%

Financials

2026 *2027 *
Net sales - -
Net income -34.89M -29.89M -27.97M -25.6M -48.04M -3.34B -48.68M -330M -129M -1.68B -131M -128M -5.55B -38.03M -32.57M -30.48M -27.9M -52.36M -3.64B -53.05M -360M -140M -1.83B -143M -140M -6.05B
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
21/08/26 US$2.540 -1.93% 25,656
20/08/26 US$2.590 -1.89% 70,954
19/08/26 US$2.640 +1.93% 62,197
18/08/26 US$2.590 -7.17% 58,563
17/08/26 US$2.790 +7.31% 192,438
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.540USD
Average target price
18.67USD
Spread / Average Target
+634.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock